A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Clinical trial NCT04380805 · COMPLETED
Trial details
- NCT number
- NCT04380805
- Sponsor
- Akeso
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-15
- Primary completion
- 2022-12-22
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.